Ozempic

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.

A functional medicine expert has cautioned that high-dose GLP-1 weight-loss drugs such as Ozempic may affect more than appetite and food cravings, suggesting possible broader disruptions to the body that are not yet fully understood. The warning comes as GLP-1 medications continue to surge in popularity for weight loss, with many users reporting unexpected side effects.

People are taking smaller-than-prescribed doses of Ozempic, known as microdosing, hoping to lose weight while avoiding side effects. An obesity medicine doctor says the practice carries risks, is not well studied, and that low doses only make sense in specific cases under medical supervision, warning against self-adjusting doses of the drug.